Scancell Hldgs Plc (LON:SCLP)
18.40p-3.16%
Spriggl Score: Weak— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Striking melanoma trial data; advanced talks for a Nasdaq listing to close the funding gap.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Scancell Hldgs Plc
Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phase II for the treatment of melanoma; and SC134, an antibody f…
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Market Cap:
- £197.2M
Recent dividends
No recent dividends recorded.
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Scancell Hldgs Plc and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free